Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
10.71
1.21 (12.74%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :148,249
Date :09-22-2017
* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Announces Successful Meeting with FDA for Oral Insulin

September 5th, 2017|

JERUSALEM, Sept. 5, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully concluded its meeting […]

Oramed to Present at the Rodman & Renshaw Global Investment Conference

August 29th, 2017|

JERUSALEM, August 29, 2017 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman […]

Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs

July 18th, 2017|

JERUSALEM, July 18, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice […]

Oramed to Present at BIT’S 5th World Congress of Diabetes on July 13, 2017

July 12th, 2017|

JERUSALEM, July 12, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed’s Chief Scientific Officer, […]